ReviewNature reviews. Rheumatology2011
Safety of biologic therapy in rheumatoid arthritis.
Review in Nature reviews. Rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 87 citations in OpenAlex.
- Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDs.Rheumatology advances in practice · 2026Article
- Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.Rheumatology (Oxford, England) · 2024Observational
- Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.Arthritis research & therapy · 2024Article
- Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective.Frontiers in immunology · 2024Review
- Rituximab, but not other biologics, impairs humoral immunity in patients with rheumatoid arthritis-a study using CoVariant protein arrays.Rheumatology advances in practice · 2023Article
- Dual-Drug Loaded Separable Microneedles for Efficient Rheumatoid Arthritis Therapy.Pharmaceutics · 2022Article
- Airway Disease in Rheumatoid Arthritis.Annals of the American Thoracic Society · 2022Review
- Total-Body PET Imaging of Musculoskeletal Disorders.PET clinics · 2021Review
- The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases.Frontiers in immunology · 2020Review
- Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?Frontiers in medicine · 2019Article
- Impact of Host Genetics and Biological Response Modifiers on Respiratory Tract Infections.Frontiers in immunology · 2019Review
- Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study.Therapeutics and clinical risk management · 2018Article
- Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad.Immunologic research · 2017Review
- Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor.Medicine · 2017Observational
- Calcium channels: the potential therapeutic targets for inflammatory bone destruction of rheumatoid arthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2016Review
- Whole-Genome Expression Analysis and Signal Pathway Screening of Synovium-Derived Mesenchymal Stromal Cells in Rheumatoid Arthritis.Stem cells international · 2016Article
- Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report.BMC pulmonary medicine · 2015Article
- Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.Annals of the rheumatic diseases · 2015Review
- Defining immunological impact and therapeutic benefit of mild heating in a murine model of arthritis.PloS one · 2015Article
- Local but Not Systemic Administration of Uridine Prevents Development of Antigen-Induced Arthritis.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologic therapies have revolutionized the treatment of rheumatic diseases in the past decade. As with any drugs, however, a variety of important safety concerns affect the choice and use of these agents. Several issues, such as the risk of infection, malignancy, or administration reactions, apply to all of these compounds, although some conditions that affect patient selection and management within these categories seem to be specific to particular biologic treatments. Other safety concerns with biologic agents, such as congestive heart failure, demyelinating disease, and hyperlipidemia, are associated with individual agents. Despite all these concerns, the therapeutic indices for biologic agents remain fairly high in relation to non-biologic DMARDs. Available safety data for all biologic agents approved for the treatment of rheumatoid arthritis are reviewed in this manuscript. With careful patient selection and appropriate vigilance on the part of treating physicians and other care providers, these compounds can be safely integrated into the therapeutic plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.